- Home
- KOPN vs CLLS Comparison
KOPN vs CLLS Comparison
Compare KOPN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOPN | CLLS |
|---|---|---|
| Founded | 1984 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.8M | 384.3M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KOPN | CLLS |
|---|---|---|
| Price | $2.58 | $3.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.25 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 3.0M | 46.4K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,044,337.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $40.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $1.17 |
| 52 Week High | $4.16 | $5.48 |
Technical Indicators
Market Signals| Indicator | KOPN | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 60.38 | 50.31 |
| Support Level | $2.24 | $3.32 |
| Resistance Level | $2.74 | $3.83 |
| Average True Range (ATR) | 0.23 | 0.20 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 87.86 | 67.35 |
Price Performance
Historical ComparisonAbout KOPN Kopin Corporation
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.